Who are Ikena Oncology, Inc.'s investors?

Ikena Oncology, Inc.'s investors include Atlas Venture, Biotechnology Value Fund, Foresite Capital, Omega Funds, OrbiMed, RTW Investments L.P..

How much funding has Ikena Oncology, Inc. raised?

Ikena Oncology, Inc. has disclosed $42.6M raised across 1 of its 3 known rounds.

Where is Ikena Oncology, Inc. headquartered?

Ikena Oncology, Inc. is headquartered in Boston, US.

Ikena Oncology, Inc.

Boston, US · Delaware corporation · 6 known investors

Biotech

Founders & leadership

Jotin MarangoExecutive

Mark ManfrediExecutive

Jeffrey EcsedyExecutive

Sergio SantillanaExecutive

Michelle ZhangExecutive

Board

Otello Stampacchia inBoard directorManaging Director at Omega Funds

Jean-Francois Formela inBoard directorPartner at Atlas Venture

Iain Dukes inBoard directorVenture Partner at OrbiMed

David Bonita inBoard directorGeneral Partner at OrbiMed

Richard WoosterBoard director

Owen HughesBoard director

Maria KoehlerBoard director

Investors · 6

Atlas VenturereportedCambridge · $500K – $1Mvia Jean-François Formela · board

Biotechnology Value FundreportedSan Francisco

Foresite CapitalreportedWest Hollywood

Omega FundsreportedBoston

OrbiMedreportedNew York · $1M – $75Mvia David Bonita · board

RTW Investments L.P.reportedNew York

Reported raises · per SEC filings

Form D private placements

$42.6M disclosed across 1 of 3 rounds · 2023–2025

▶$75MofferedJul 2025 · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Richard WoosterDirector
Otello StampacchiaDirector
Jotin MarangoExecutive Officer
Jean-Francois FormelaDirector
Mark ManfrediExecutive Officer, Director
Jeffrey EcsedyExecutive Officer
Owen HughesDirector
Iain DukesDirector
Maria KoehlerDirector
David BonitaDirector

Offering amount: $75M
Placement agents: LEERINK PARTNERS LLC
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$42.6MraisedAug 2023 · 48 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Maria KoehlerDirector
Sergio SantillanaExecutive Officer
Richard WoosterDirector
Michelle ZhangExecutive Officer
Jotin MarangoExecutive Officer
Jeffrey EcsedyExecutive Officer
Iain D. DukesDirector
Owen HughesDirector
Mark ManfrediExecutive Officer, Director
Otello StampacchiaDirector
Jean-Francois FormelaDirector
David BonitaDirector

Offering amount: $42.6M
Amount sold: $42.6M
First sale: Aug 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Ikena Oncology, Inc. announced that it expects to receive $75 million in funding from a group of investors - MarketScreenermarketscreener.com · Dec 2024

Ikena Oncology, Inc. (IKNA): history, ownership, mission, how it works & makes money – DCFmodeling.comdcfmodeling.com · Jun 2024

Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 | Business Wirebusinesswire.com · May 2021

Frequently asked questions

Who are Ikena Oncology, Inc.'s investors?: Ikena Oncology, Inc.'s investors include Atlas Venture, Biotechnology Value Fund, Foresite Capital, Omega Funds, OrbiMed, RTW Investments L.P..
How much funding has Ikena Oncology, Inc. raised?: Ikena Oncology, Inc. has disclosed $42.6M raised across 1 of its 3 known rounds.
Where is Ikena Oncology, Inc. headquartered?: Ikena Oncology, Inc. is headquartered in Boston, US.